Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer - Sartor, Oliver; de Bono, Johann; Chi, Kim N; Fizazi, Karim; Herrmann, Ken; Rahbar, Kambiz; Tagawa, Scott T; Nordquist, Luke T; Vaishampayan, Nitin; El-Haddad, Ghassan; Park, Chandler H; Beer, Tomasz M; et al. (The New England journal of medicine, 2021)
Keywords: Adverse events; Aged; Aged, 80 and over; Androgen receptors; Androgens; Antigens; Biomarkers; Cancer therapies; Castration; Chemotherapy; Combined Modality Therapy; Computed tomography; Dipeptides - therapeutic use; Disease control; Drug dosages; Drug withdrawal; FDA approval; Gallium; Hematology; Heterocyclic Compounds, 1-Ring - therapeutic use; Humans; Immunotherapy; Kallikreins - antagonists & inhibitors; Lutetium - adverse effects; Lutetium - therapeutic use; Magnetic resonance imaging; Male; Medical prognosis; Metastases; Metastasis; Microenvironments; Middle Aged; Oncology; Pain; Patients; Positron-Emission Tomography; Prostate - diagnostic imaging; Prostate cancer; Prostate Disease; Prostate Disease General; Prostate-Specific Antigen - antagonists & inhibitors; Prostate-Specific Antigen - therapeutic use; Prostatic Neoplasms, Castration-Resistant - diagnostic imaging; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - radiotherapy; Quality of life; Radiation; Radioisotopes - adverse effects; Radioisotopes - therapeutic use; Radium; Survival Analysis; Treatments in Oncology; Urology